Increased α-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson’s disease
•PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from...
Saved in:
Published in | Neuroscience Vol. 567; pp. 28 - 36 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
16.02.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 0306-4522 1873-7544 1873-7544 |
DOI | 10.1016/j.neuroscience.2024.12.056 |
Cover
Abstract | •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from HCs.
The brain of patients with Parkinson’s disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression. |
---|---|
AbstractList | •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from HCs.
The brain of patients with Parkinson’s disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression. The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression. The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression. |
Author | Li, Pengjie Yu, Xiaohan Deng, Yeyun Li, Xuran Wang, Chaodong Li, Xin Yin, Na Wang, Yiming Yu, Shun |
Author_xml | – sequence: 1 givenname: Na surname: Yin fullname: Yin, Na organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 2 givenname: Pengjie surname: Li fullname: Li, Pengjie organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 3 givenname: Xuran surname: Li fullname: Li, Xuran organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 4 givenname: Xin surname: Li fullname: Li, Xin organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 5 givenname: Yiming surname: Wang fullname: Wang, Yiming organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 6 givenname: Xiaohan surname: Yu fullname: Yu, Xiaohan organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 7 givenname: Yeyun surname: Deng fullname: Deng, Yeyun organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 8 givenname: Chaodong surname: Wang fullname: Wang, Chaodong organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China – sequence: 9 givenname: Shun surname: Yu fullname: Yu, Shun email: yushun103@163.com, yushun103@hotmail.com organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39742943$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtu1TAUhi1URG8LW0AWIyYJfsR5MIPyqlQJBjC2HOeY-taxL3ZSlE5gGyyDjbAIVoKje3mIUS1Zlqzv_y2f7wQd-eABoUeUlJTQ-sm29DDHkLQFr6FkhFUlZSUR9R20oW3Di0ZU1RHaEE7qohKMHaOTlLYkL1Hxe-iYd03Fuopv0JdzryOoBAP-8b1Ii5-1A-vx7jKkvOPi1GSDx8oPODj7MYwQ7c3fO-UmiDkM_mYZIeE16lQaFQ4G7zIHfkr4s50u8TsVr6xPwf_8-i3hwab12fvorlEuwYPDeYo-vHr5_uxNcfH29fnZs4tC85ZNBa2NqHsziA4aCn1tmDbtoFTb1LzXBhhlLM-hh45rQuqh6qjhLSUd1UKBavgperzv3cXwaYY0ydEmDc4pD2FOklNBWi6adkUfHtC5H2GQu2hHFRf5e2gZeLoHdJaQIpg_CCVyNSS38l9DcjUkKZPZUA6_2Ich__baQpQHarAR9CSHYG9X8_y_Gu2st1q5K1huW_ILjEW8YA |
Cites_doi | 10.3390/ijms23116216 10.1111/jnc.14809 10.3390/cells8040364 10.3233/JPD-160779 10.1074/jbc.M208046200 10.3390/jcm8101601 10.1016/j.neuroscience.2015.05.035 10.1021/acschemneuro.8b00383 10.3390/ijms241310932 10.1016/j.neurobiolaging.2015.06.004 10.1016/S0140-6736(21)00218-X 10.1007/s11910-018-0860-4 10.1007/s00441-004-0956-9 10.3389/fnins.2018.00080 10.1038/emm.2001.39 10.1007/s00018-022-04240-2 10.1016/j.parkreldis.2022.06.001 10.3389/fgene.2014.00382 10.1074/jbc.274.29.20313 10.3390/ijms21228645 10.1016/j.parkreldis.2018.10.003 10.1074/jbc.C800206200 10.1016/j.nbd.2021.105291 10.1074/jbc.M600933200 10.3389/fnagi.2021.623977 10.2188/jea.12.280 10.1016/j.neuroscience.2013.09.061 10.1016/S0021-9258(18)82288-8 10.1038/s41593-019-0423-2 10.1007/s10072-020-04407-4 10.1042/bse0560125 10.1111/jnc.13234 10.1186/s40478-017-0452-6 10.1523/JNEUROSCI.6513-10.2011 10.1016/S0197-4580(02)00065-9 10.1038/cddis.2014.175 10.1016/j.neuroscience.2012.01.028 10.1002/mds.26424 10.1016/j.peptides.2014.09.018 10.1016/j.mcn.2018.12.005 10.1074/jbc.M109.081950 |
ContentType | Journal Article |
Copyright | 2025 International Brain Research Organization (IBRO) Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2025 International Brain Research Organization (IBRO) – notice: Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.neuroscience.2024.12.056 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1873-7544 |
EndPage | 36 |
ExternalDocumentID | 39742943 10_1016_j_neuroscience_2024_12_056 S0306452224007632 |
Genre | Journal Article |
GroupedDBID | --- --K --M -DZ -~X .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5RE 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABCQJ ABFNM ABFRF ABJNI ABLJU ABMAC ABTEW ACDAQ ACGFO ACGFS ACIUM ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP AXJTR BKOJK BLXMC CS3 DU5 EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HMQ IHE J1W KOM L7B M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SSN SSZ T5K UNMZH Z5R ~G- AFCTW AGRNS BNPGV SSH .55 .GJ 29N 53G 5VS AAQXK AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO AGHFR AGQPQ AHHHB ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HVGLF HZ~ R2- RIG SNS WUQ X7M YYP ZGI ZXP AACTN CGR CUY CVF ECM EIF NPM 7X8 EFLBG |
ID | FETCH-LOGICAL-c382t-16f56bfd59e71eb6f2cf8daa8763bcfe2122202be93c006d491f381091c5aea73 |
IEDL.DBID | AIKHN |
ISSN | 0306-4522 1873-7544 |
IngestDate | Thu Sep 04 23:54:28 EDT 2025 Thu May 01 02:19:42 EDT 2025 Tue Aug 05 12:08:54 EDT 2025 Sat Jun 28 18:17:05 EDT 2025 Tue Aug 26 20:14:02 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Phosphorylation MoCA H&Y stage LRRK2 M-α-syn pS-α-syn AUC SD GRKs L-DOPA LEDD α-synuclein UPDRS III O-α-syn GCase Oligomerization Enzyme PLK2 ROC PP2A LNs SDS-PAGE HAMD PD α-syn GlcCer HC LBs Parkinson’s disease ELISA |
Language | English |
License | Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c382t-16f56bfd59e71eb6f2cf8daa8763bcfe2122202be93c006d491f381091c5aea73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 39742943 |
PQID | 3150835787 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_3150835787 pubmed_primary_39742943 crossref_primary_10_1016_j_neuroscience_2024_12_056 elsevier_sciencedirect_doi_10_1016_j_neuroscience_2024_12_056 elsevier_clinicalkey_doi_10_1016_j_neuroscience_2024_12_056 |
PublicationCentury | 2000 |
PublicationDate | 2025-02-16 |
PublicationDateYYYYMMDD | 2025-02-16 |
PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-16 day: 16 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Neuroscience |
PublicationTitleAlternate | Neuroscience |
PublicationYear | 2025 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Sui, Bullock, Erickson, Zhang, Banks (b0170) 2014; 62 Zhang, Zhu, Sun, Zhi, Ding, Yuan (b0210) 2019; 60 Chalfant, Kishikawa, Mumby, Kamibayashi, Bielawska, Hannun (b0040) 1999; 274 Paul, Qureshi, Rana (b0145) 2020; 41 Chen, Yang, Li, Li, Yang, Xu, Yu (b0045) 2015; 300 Liu, Chen, Mi, Yang, Li, Wang (b0120) 2015; 36 Shahmoradian, Lewis, Genoud, Hench, Moors, Navarro (b0165) 2019; 22 Lee, Chen, Junn, Im, Grosso, Sonsalla (b0100) 2011; 31 Pérez-Revuelta, Hettich, Ciociaro, Rotermund, Kahle, Krauss, Di Monte (b0150) 2014; 5 Tofaris (b0180) 2022; 79 Oueslati (b0140) 2016; 6 Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of α-Synuclein Oligomers in Parkinson's Disease. Jiang, Tang, Meng, Futatsuka (b0090) 2002; 12 Arawaka, Sato, Sasaki, Koyama, Kato (b0010) 2017; 5 Postuma, Berg, Stern, Poewe, Olanow, Oertel (b0155) 2015; 30 8(4). doi: ARTN 36410.3390/cells8040364. Taymans, Baekelandt (b0175) 2014; 5 Lin, C.H., Liu, H.C., Yang, S.Y., Yang, K.C., Wu, C.C., and Chiu, M.J. (2019). Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. 8(10). doi: ARTN 160110.3390/jcm8101601. Weston, Cook, Stackhouse, Sal, Schultz, Tobias (b0190) 2021; 152 Bergeron, Motter, Tanaka, Fauss, Babcock, Chiou (b0015) 2014; 256 Braak, Del Tredici, Rüb, de Vos, Jansen Steur, Braak (b0025) 2003; 24 Inglis, Chereau, Brigham, Chiou, Schöbel, Frigon (b0085) 2009; 284 Wu, Lou, Alerte, Stachowski, Chen, Singleton (b0195) 2012; 207 Dobrowsky, Kamibayashi, Mumby, Hannun (b0055) 1993; 268 Maass, Schulz, Lingor, Mollenhauer, Bähr (b0130) 2019; 97 Bloem, Okun, Klein (b0020) 2021; 397 Bridi, Hirth (b0035) 2018; 12 Li, Yuan, Li, Han, Liu, Yang (b0110) 2021; 2021 Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cocco, Manai, Manca, Noli (b0050) 2023; 24 21(22). doi: ARTN 864510.3390/ijms21228645. Hasegawa, Fujiwara, Nonaka, Wakabayashi, Takahashi, Lee (b0080) 2002; 277 Anderson, Walker, Goldstein, de Laat, Banducci, Caccavello (b0005) 2006; 281 Mbefo, Paleologou, Boucharaba, Oueslati, Schell, Fournier (b0135) 2010; 285 Xu, Deng, Qing (b0200) 2015; 135 18(8). doi: ARTN 4410.1007/s11910-018-0860-4. Wang, Li, Li, Yang, Yu (b0185) 2016; 2016 Ma, Liu, Wang, Zhang, Kou, Feng (b0125) 2019; 10 Yu, Chan (b0205) 2014; 56 Kawahata, Finkelstein, Fukunaga (b0095) 2022; 23 Fayyad, Salim, Majbour, Erskine, Stoops, Mollenhauer, El-Agnaf (b0065) 2019; 150 Zubelzu, Morera-Herreras, Irastorza, Gómez-Esteban, Murueta-Goyena (b0215) 2022; 99 Galadari, Hago, Patel (b0070) 2001; 33 Gan-Or, Z., Liong, C., and Alcalay, R.N. (2018). GBA-Associated Parkinson's Disease and Other Synucleinopathies. Li, Li, Li, Li, Sun, Yang (b0105) 2021; 13 Braak, Ghebremedhin, Rüb, Bratzke, Del Tredici (b0030) 2004; 318 Weston (10.1016/j.neuroscience.2024.12.056_b0190) 2021; 152 Anderson (10.1016/j.neuroscience.2024.12.056_b0005) 2006; 281 Maass (10.1016/j.neuroscience.2024.12.056_b0130) 2019; 97 Oueslati (10.1016/j.neuroscience.2024.12.056_b0140) 2016; 6 Galadari (10.1016/j.neuroscience.2024.12.056_b0070) 2001; 33 Chen (10.1016/j.neuroscience.2024.12.056_b0045) 2015; 300 Sui (10.1016/j.neuroscience.2024.12.056_b0170) 2014; 62 Braak (10.1016/j.neuroscience.2024.12.056_b0025) 2003; 24 10.1016/j.neuroscience.2024.12.056_b0075 Tofaris (10.1016/j.neuroscience.2024.12.056_b0180) 2022; 79 Cocco (10.1016/j.neuroscience.2024.12.056_b0050) 2023; 24 Bergeron (10.1016/j.neuroscience.2024.12.056_b0015) 2014; 256 Dobrowsky (10.1016/j.neuroscience.2024.12.056_b0055) 1993; 268 Arawaka (10.1016/j.neuroscience.2024.12.056_b0010) 2017; 5 Ma (10.1016/j.neuroscience.2024.12.056_b0125) 2019; 10 Shahmoradian (10.1016/j.neuroscience.2024.12.056_b0165) 2019; 22 Wang (10.1016/j.neuroscience.2024.12.056_b0185) 2016; 2016 Chalfant (10.1016/j.neuroscience.2024.12.056_b0040) 1999; 274 10.1016/j.neuroscience.2024.12.056_b0115 Inglis (10.1016/j.neuroscience.2024.12.056_b0085) 2009; 284 Bridi (10.1016/j.neuroscience.2024.12.056_b0035) 2018; 12 Hasegawa (10.1016/j.neuroscience.2024.12.056_b0080) 2002; 277 Xu (10.1016/j.neuroscience.2024.12.056_b0200) 2015; 135 Mbefo (10.1016/j.neuroscience.2024.12.056_b0135) 2010; 285 Jiang (10.1016/j.neuroscience.2024.12.056_b0090) 2002; 12 Kawahata (10.1016/j.neuroscience.2024.12.056_b0095) 2022; 23 Liu (10.1016/j.neuroscience.2024.12.056_b0120) 2015; 36 Pérez-Revuelta (10.1016/j.neuroscience.2024.12.056_b0150) 2014; 5 Yu (10.1016/j.neuroscience.2024.12.056_b0205) 2014; 56 10.1016/j.neuroscience.2024.12.056_b0060 Paul (10.1016/j.neuroscience.2024.12.056_b0145) 2020; 41 10.1016/j.neuroscience.2024.12.056_b0160 Taymans (10.1016/j.neuroscience.2024.12.056_b0175) 2014; 5 Zubelzu (10.1016/j.neuroscience.2024.12.056_b0215) 2022; 99 Postuma (10.1016/j.neuroscience.2024.12.056_b0155) 2015; 30 Wu (10.1016/j.neuroscience.2024.12.056_b0195) 2012; 207 Fayyad (10.1016/j.neuroscience.2024.12.056_b0065) 2019; 150 Li (10.1016/j.neuroscience.2024.12.056_b0110) 2021; 2021 Li (10.1016/j.neuroscience.2024.12.056_b0105) 2021; 13 Braak (10.1016/j.neuroscience.2024.12.056_b0030) 2004; 318 Bloem (10.1016/j.neuroscience.2024.12.056_b0020) 2021; 397 Zhang (10.1016/j.neuroscience.2024.12.056_b0210) 2019; 60 Lee (10.1016/j.neuroscience.2024.12.056_b0100) 2011; 31 |
References_xml | – reference: . 21(22). doi: ARTN 864510.3390/ijms21228645. – volume: 12 start-page: 280 year: 2002 end-page: 286 ident: b0090 article-title: Demographic determinants for change in activities of daily living: a cohort study of the elderly people in Beijing – volume: 30 start-page: 1591 year: 2015 end-page: 1601 ident: b0155 article-title: MDS clinical diagnostic criteria for Parkinson's disease – volume: 5 start-page: 382 year: 2014 ident: b0175 article-title: Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism – volume: 60 start-page: 57 year: 2019 end-page: 63 ident: b0210 article-title: Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease – volume: 99 start-page: 107 year: 2022 end-page: 115 ident: b0215 article-title: Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis publication-title: . – volume: 150 start-page: 626 year: 2019 end-page: 636 ident: b0065 article-title: Parkinson's disease biomarkers based on α-synuclein – volume: 277 start-page: 49071 year: 2002 end-page: 49076 ident: b0080 article-title: Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions – volume: 24 year: 2023 ident: b0050 article-title: Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease – reference: 8(10). doi: ARTN 160110.3390/jcm8101601. – volume: 10 start-page: 812 year: 2019 end-page: 823 ident: b0125 article-title: Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease – volume: 300 start-page: 297 year: 2015 end-page: 306 ident: b0045 article-title: α-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation – reference: 18(8). doi: ARTN 4410.1007/s11910-018-0860-4. – volume: 22 year: 2019 ident: b0165 article-title: Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes – reference: Lin, C.H., Liu, H.C., Yang, S.Y., Yang, K.C., Wu, C.C., and Chiu, M.J. (2019). Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. – volume: 56 start-page: 125 year: 2014 end-page: 135 ident: b0205 article-title: Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease – volume: 281 start-page: 29739 year: 2006 end-page: 29752 ident: b0005 article-title: Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease – volume: 36 start-page: 2649 year: 2015 end-page: 2659 ident: b0120 article-title: Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains – volume: 23 year: 2022 ident: b0095 article-title: Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies – volume: 97 start-page: 60 year: 2019 end-page: 66 ident: b0130 article-title: Cerebrospinal fluid biomarker for Parkinson's disease: An overview – reference: 8(4). doi: ARTN 36410.3390/cells8040364. – reference: Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. – volume: 135 start-page: 4 year: 2015 end-page: 18 ident: b0200 article-title: The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease – volume: 41 start-page: 2691 year: 2020 end-page: 2701 ident: b0145 article-title: Peripheral neuropathy in Parkinson's disease – volume: 256 start-page: 72 year: 2014 end-page: 82 ident: b0015 article-title: In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain – volume: 6 start-page: 39 year: 2016 end-page: 51 ident: b0140 article-title: Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? – volume: 268 start-page: 15523 year: 1993 end-page: 15530 ident: b0055 article-title: Ceramide activates heterotrimeric protein phosphatase 2A – volume: 318 start-page: 121 year: 2004 end-page: 134 ident: b0030 article-title: Stages in the development of Parkinson's disease-related pathology – volume: 62 start-page: 197 year: 2014 end-page: 202 ident: b0170 article-title: Alpha synuclein is transported into and out of the brain by the blood-brain barrier – volume: 397 start-page: 2284 year: 2021 end-page: 2303 ident: b0020 article-title: Parkinson's disease – volume: 31 start-page: 6963 year: 2011 end-page: 6971 ident: b0100 article-title: Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model – volume: 2021 year: 2021 ident: b0110 article-title: Inhibition of α-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice – reference: Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of α-Synuclein Oligomers in Parkinson's Disease. – volume: 13 year: 2021 ident: b0105 article-title: Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease – volume: 2016 year: 2016 ident: b0185 article-title: Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity – volume: 284 start-page: 2598 year: 2009 end-page: 2602 ident: b0085 article-title: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system – volume: 79 start-page: 210 year: 2022 ident: b0180 article-title: Initiation and progression of α-synuclein pathology in Parkinson's disease – volume: 12 year: 2018 ident: b0035 article-title: Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease – volume: 274 start-page: 20313 year: 1999 end-page: 20317 ident: b0040 article-title: Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid – volume: 285 start-page: 2807 year: 2010 end-page: 2822 ident: b0135 article-title: Phosphorylation of Synucleins by Members of the Polo-like Kinase Family – volume: 152 year: 2021 ident: b0190 article-title: In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129 publication-title: . – volume: 33 start-page: 240 year: 2001 end-page: 244 ident: b0070 article-title: Effects of cations on ceramide-activated protein phosphatase 2A – volume: 5 year: 2014 ident: b0150 article-title: Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation – reference: Gan-Or, Z., Liong, C., and Alcalay, R.N. (2018). GBA-Associated Parkinson's Disease and Other Synucleinopathies. – volume: 5 year: 2017 ident: b0010 article-title: Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates – volume: 24 start-page: 197 year: 2003 end-page: 211 ident: b0025 article-title: Staging of brain pathology related to sporadic Parkinson's disease – volume: 207 start-page: 288 year: 2012 end-page: 297 ident: b0195 article-title: Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo – volume: 23 issue: 11 year: 2022 ident: 10.1016/j.neuroscience.2024.12.056_b0095 article-title: Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23116216 – volume: 150 start-page: 626 issue: 5 year: 2019 ident: 10.1016/j.neuroscience.2024.12.056_b0065 article-title: Parkinson's disease biomarkers based on α-synuclein publication-title: J. Neurochem. doi: 10.1111/jnc.14809 – ident: 10.1016/j.neuroscience.2024.12.056_b0160 doi: 10.3390/cells8040364 – volume: 6 start-page: 39 issue: 1 year: 2016 ident: 10.1016/j.neuroscience.2024.12.056_b0140 article-title: Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? publication-title: J. Parkinsons Dis. doi: 10.3233/JPD-160779 – volume: 277 start-page: 49071 issue: 50 year: 2002 ident: 10.1016/j.neuroscience.2024.12.056_b0080 article-title: Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions publication-title: J. Biol. Chem. doi: 10.1074/jbc.M208046200 – ident: 10.1016/j.neuroscience.2024.12.056_b0115 doi: 10.3390/jcm8101601 – volume: 2016 year: 2016 ident: 10.1016/j.neuroscience.2024.12.056_b0185 article-title: Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity publication-title: Parkinsons Dis. – volume: 300 start-page: 297 year: 2015 ident: 10.1016/j.neuroscience.2024.12.056_b0045 article-title: α-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation publication-title: Neuroscience doi: 10.1016/j.neuroscience.2015.05.035 – volume: 10 start-page: 812 issue: 2 year: 2019 ident: 10.1016/j.neuroscience.2024.12.056_b0125 article-title: Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease publication-title: ACS Chem. Neurosci. doi: 10.1021/acschemneuro.8b00383 – volume: 24 issue: 13 year: 2023 ident: 10.1016/j.neuroscience.2024.12.056_b0050 article-title: Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms241310932 – volume: 36 start-page: 2649 issue: 9 year: 2015 ident: 10.1016/j.neuroscience.2024.12.056_b0120 article-title: Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2015.06.004 – volume: 397 start-page: 2284 issue: 10291 year: 2021 ident: 10.1016/j.neuroscience.2024.12.056_b0020 article-title: Parkinson's disease publication-title: Lancet doi: 10.1016/S0140-6736(21)00218-X – ident: 10.1016/j.neuroscience.2024.12.056_b0075 doi: 10.1007/s11910-018-0860-4 – volume: 318 start-page: 121 issue: 1 year: 2004 ident: 10.1016/j.neuroscience.2024.12.056_b0030 article-title: Stages in the development of Parkinson's disease-related pathology publication-title: Cell Tissue Res. doi: 10.1007/s00441-004-0956-9 – volume: 12 year: 2018 ident: 10.1016/j.neuroscience.2024.12.056_b0035 article-title: Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease publication-title: Front. Neurosci. doi: 10.3389/fnins.2018.00080 – volume: 33 start-page: 240 issue: 4 year: 2001 ident: 10.1016/j.neuroscience.2024.12.056_b0070 article-title: Effects of cations on ceramide-activated protein phosphatase 2A publication-title: Exp. Mo.l Med. doi: 10.1038/emm.2001.39 – volume: 79 start-page: 210 issue: 4 year: 2022 ident: 10.1016/j.neuroscience.2024.12.056_b0180 article-title: Initiation and progression of α-synuclein pathology in Parkinson's disease publication-title: Cell Mol. Life Sci. doi: 10.1007/s00018-022-04240-2 – volume: 99 start-page: 107 year: 2022 ident: 10.1016/j.neuroscience.2024.12.056_b0215 article-title: Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2022.06.001 – volume: 5 start-page: 382 year: 2014 ident: 10.1016/j.neuroscience.2024.12.056_b0175 article-title: Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism publication-title: Front. Genet. doi: 10.3389/fgene.2014.00382 – volume: 274 start-page: 20313 issue: 29 year: 1999 ident: 10.1016/j.neuroscience.2024.12.056_b0040 article-title: Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid publication-title: J. Biol. Chem. doi: 10.1074/jbc.274.29.20313 – ident: 10.1016/j.neuroscience.2024.12.056_b0060 doi: 10.3390/ijms21228645 – volume: 60 start-page: 57 year: 2019 ident: 10.1016/j.neuroscience.2024.12.056_b0210 article-title: Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2018.10.003 – volume: 284 start-page: 2598 issue: 5 year: 2009 ident: 10.1016/j.neuroscience.2024.12.056_b0085 article-title: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system publication-title: J. Biol. Chem. doi: 10.1074/jbc.C800206200 – volume: 152 year: 2021 ident: 10.1016/j.neuroscience.2024.12.056_b0190 article-title: In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129 publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2021.105291 – volume: 281 start-page: 29739 issue: 40 year: 2006 ident: 10.1016/j.neuroscience.2024.12.056_b0005 article-title: Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease publication-title: J. Biol. Chem. doi: 10.1074/jbc.M600933200 – volume: 13 year: 2021 ident: 10.1016/j.neuroscience.2024.12.056_b0105 article-title: Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease publication-title: Front. Aging Neurosci. doi: 10.3389/fnagi.2021.623977 – volume: 12 start-page: 280 issue: 3 year: 2002 ident: 10.1016/j.neuroscience.2024.12.056_b0090 article-title: Demographic determinants for change in activities of daily living: a cohort study of the elderly people in Beijing publication-title: J. Epidemiol. doi: 10.2188/jea.12.280 – volume: 2021 year: 2021 ident: 10.1016/j.neuroscience.2024.12.056_b0110 article-title: Inhibition of α-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice publication-title: Oxid. Med. Cell Longev. – volume: 256 start-page: 72 year: 2014 ident: 10.1016/j.neuroscience.2024.12.056_b0015 article-title: In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain publication-title: Neuroscience doi: 10.1016/j.neuroscience.2013.09.061 – volume: 268 start-page: 15523 issue: 21 year: 1993 ident: 10.1016/j.neuroscience.2024.12.056_b0055 article-title: Ceramide activates heterotrimeric protein phosphatase 2A publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)82288-8 – volume: 22 issue: 7 year: 2019 ident: 10.1016/j.neuroscience.2024.12.056_b0165 article-title: Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes publication-title: Nat. Neurosci. doi: 10.1038/s41593-019-0423-2 – volume: 41 start-page: 2691 issue: 10 year: 2020 ident: 10.1016/j.neuroscience.2024.12.056_b0145 article-title: Peripheral neuropathy in Parkinson's disease publication-title: Neurol. Sci. doi: 10.1007/s10072-020-04407-4 – volume: 56 start-page: 125 year: 2014 ident: 10.1016/j.neuroscience.2024.12.056_b0205 article-title: Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease publication-title: Essays Biochem. doi: 10.1042/bse0560125 – volume: 135 start-page: 4 issue: 1 year: 2015 ident: 10.1016/j.neuroscience.2024.12.056_b0200 article-title: The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease publication-title: J. Neurochem. doi: 10.1111/jnc.13234 – volume: 5 year: 2017 ident: 10.1016/j.neuroscience.2024.12.056_b0010 article-title: Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates publication-title: Acta. Neuropathol. Commun. doi: 10.1186/s40478-017-0452-6 – volume: 31 start-page: 6963 issue: 19 year: 2011 ident: 10.1016/j.neuroscience.2024.12.056_b0100 article-title: Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.6513-10.2011 – volume: 24 start-page: 197 issue: 2 year: 2003 ident: 10.1016/j.neuroscience.2024.12.056_b0025 article-title: Staging of brain pathology related to sporadic Parkinson's disease publication-title: Neurobiol. Aging doi: 10.1016/S0197-4580(02)00065-9 – volume: 5 year: 2014 ident: 10.1016/j.neuroscience.2024.12.056_b0150 article-title: Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation publication-title: Cell Death Dis. doi: 10.1038/cddis.2014.175 – volume: 207 start-page: 288 year: 2012 ident: 10.1016/j.neuroscience.2024.12.056_b0195 article-title: Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo publication-title: Neuroscience doi: 10.1016/j.neuroscience.2012.01.028 – volume: 30 start-page: 1591 issue: 12 year: 2015 ident: 10.1016/j.neuroscience.2024.12.056_b0155 article-title: MDS clinical diagnostic criteria for Parkinson's disease publication-title: Mov. Disord. doi: 10.1002/mds.26424 – volume: 62 start-page: 197 year: 2014 ident: 10.1016/j.neuroscience.2024.12.056_b0170 article-title: Alpha synuclein is transported into and out of the brain by the blood-brain barrier publication-title: Peptides doi: 10.1016/j.peptides.2014.09.018 – volume: 97 start-page: 60 year: 2019 ident: 10.1016/j.neuroscience.2024.12.056_b0130 article-title: Cerebrospinal fluid biomarker for Parkinson's disease: An overview publication-title: Mol. Cell Neurosci. doi: 10.1016/j.mcn.2018.12.005 – volume: 285 start-page: 2807 issue: 4 year: 2010 ident: 10.1016/j.neuroscience.2024.12.056_b0135 article-title: Phosphorylation of Synucleins by Members of the Polo-like Kinase Family publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.081950 |
SSID | ssj0000543 |
Score | 2.4671652 |
Snippet | •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of... The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 28 |
SubjectTerms | Aged alpha-Synuclein - blood alpha-Synuclein - metabolism Ceramides - blood Enzyme Female Glucosylceramidase - blood Humans Male Middle Aged Oligomerization Parkinson Disease - blood Parkinson Disease - enzymology Parkinson’s disease Phosphorylation Protein Phosphatase 2 - blood Protein Serine-Threonine Kinases - blood Protein Serine-Threonine Kinases - metabolism α-synuclein |
Title | Increased α-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson’s disease |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0306452224007632 https://dx.doi.org/10.1016/j.neuroscience.2024.12.056 https://www.ncbi.nlm.nih.gov/pubmed/39742943 https://www.proquest.com/docview/3150835787 |
Volume | 567 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELbK9sIFAeVnC1RGQtzMbmzHG6vqYVW1WqjaC1TqzUpiG7bqOqtme9geoK_BY_AifQiepDNO0h-pSJU45GJllMRjz0w833xDyAer4I_aqiFzhbdMpqJk4PQk467IJOfFyMYeS_sHanIovxylRytku6uFQVhla_sbmx6tdTsyaGdzMJ9OB18x2kU-cERBwi4BO7zKhVZpj6yOP-9NDm4MctqA5-B-hgId92iEed2ijUTWTC7j6SD2s77fT_0rDo3-aPcpedIGknTcvOszsuLCc7I2DvATPVvSjzRCO-OZ-Rr5BVYAwefO0ss_rF4GJDGeBjr_UdVwnS4bQBzNg6XVyfR7hWmc85uxmFIHYRfOlzNXUxSFqHuW08rTlpm1pnikS7GKOhaU_b34XdM2_fOCHO7ufNuesLbzAitFxhcsUT5VoLxUu1HiCuV56TOb50hfV5Tegb_jMFeF06KEbWulTjxShemkTHOXj8RL0gtVcK8Jtc7pofWp0FZJK7wuJXKPDjOrrcy46xPRzbOZNwQbpkOeHZvb2jGoHZNwA9rpk81OJaYrIQWjZ8APPEh661r6zmJ7sPz7bhUY2I2YYsmDq85qIyK9PlrBPnnVLI_rr4LID5y_FOv_-fQ35DHHJsTYlUa9Jb3F6Zl7B5HRotggjz79TDba9X8F4fsUoQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELaqcqCXCligCxRcCXELu7GdbCLUQ1VRLfTnQiv1ZiXxuN2q66ya7WF7AF6Dx-BF-hB9EmacZHeRqFSJQy5WRk489szY8_kbxt6bGHfUJu4HkFsTqEgWATo9FQjIEyVEPjC-xtLhUTw8UV9Po9MVttvehSFYZWP7a5vurXXT0mtGszcZjXrfKNolPnBCQeIqQTv8CPsaEK7v4_cFzgNjkrpGMm6d6fWWedSDvJZII4kzUyh_NkjVrP_tpe6LQr032nvC1pswku_UX_qUrYB7xjo7DrfQ4xn_wD2w05-Yd9gPtAEEPQfDb38H1cwRhfHI8cl5WeFzNavhcDxzhpeXo7OSkjg3izafUEdhcDezMVScRDHmHme8tLzhZa04HehyukPtr5Pd_fxV8Sb585yd7H0-3h0GTd2FoJCJmAZhbKMYVRelMAghj60obGKyjMjr8sICejuBY5VDKgtctEaloSWisDQsogyygXzBVl3pYINxA5D2jY1kamJlpE0LRcyj_cSkRiUCuky246wnNb2GbnFnF3pZO5q0o0OhUTtd9qlViW4vkKLJ0-gFHiS9PZf-a6o9WH6rnQUa1yIlWDIH5XWlpSfXJxvYZS_r6TH_K4z70PUr-eo_e3_HHg-PDw_0wZej_ddsTVA5YqpPE79hq9Ora9jEGGmav_Vr4A9J6RVs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+%CE%B1-synuclein+phosphorylation+and+oligomerization+and+altered+enzymes+in+plasma+of+patients+with+Parkinson%27s+disease&rft.jtitle=Neuroscience&rft.au=Yin%2C+Na&rft.au=Li%2C+Pengjie&rft.au=Li%2C+Xuran&rft.au=Li%2C+Xin&rft.date=2025-02-16&rft.eissn=1873-7544&rft.volume=567&rft.spage=28&rft_id=info:doi/10.1016%2Fj.neuroscience.2024.12.056&rft_id=info%3Apmid%2F39742943&rft.externalDocID=39742943 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-4522&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-4522&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-4522&client=summon |